Psyched Wellness Successfully Extracts Psychedelic Mushroom
Psyched Wellness (CSE: PSYC) has successfully completed its first extraction of the amanita muscaria mushroom. The mushroom was extracted as per the previously announced extraction protocol, with samples then packed and sent to an independent lab for analysis.
The mushroom itself is said to have been sourced from five different suppliers located from different geographic regions around the globe. With the extracts completed and sent for analysis, the lab will begin testing the extract for the desired compounds from the legal psychedelic mushroom. A report is expected in 5-7 days from the analysis.
Once received, the company will be able to confirm the accuracy of their extraction protocol, and ensure the specifications are sufficient for its flagship product, which is an amanita muscaria extract.
“Our scientific team is working around the clock to ensure we achieve these key milestones in a timely fashion. Once we finalize our specifications, we will be able to produce our first large-scale extraction that will be used for our pre-clinical trials, the accelerated stability tests and all of our scientific needs.”
David Shisel, COO of Psyched Wellness
Psyched Wellness last traded at $0.39 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
